Denmark-based AI immunology company Evaxion Biotech has priced its initial public offering (IPO) of 3,750,000 American Depositary Shares (ADS) and associated warrants at USD 4.00 per ADS, raising an aggregate of USD 15 million. The offer is expected to close on February 5, 2024.
The proceeds will be used to advance Evaxion's preclinical and clinical pipeline and support ongoing operational costs and working capital.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.